Organogenesis (NASDAQ:ORGO) Now Covered by Truist Financial

Stock analysts at Truist Financial initiated coverage on shares of Organogenesis (NASDAQ:ORGO) in a note issued to investors on Thursday,Benzinga reports. The brokerage set a “hold” rating and a $3.00 price target on the stock. Truist Financial’s price target would suggest a potential upside of 12.78% from the stock’s current price.

Other analysts have also recently issued research reports about the stock. Weiss Ratings cut shares of Organogenesis from a “hold (c)” rating to a “sell (d)” rating in a research note on Monday, May 11th. BTIG Research lowered shares of Organogenesis from a “buy” rating to a “neutral” rating in a report on Friday, May 8th. Finally, Wall Street Zen downgraded shares of Organogenesis from a “buy” rating to a “sell” rating in a research report on Saturday, May 9th. One analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $6.67.

Organogenesis Stock Performance

NASDAQ ORGO opened at $2.66 on Thursday. The firm’s fifty day moving average price is $2.44 and its two-hundred day moving average price is $3.73. The stock has a market cap of $342.29 million, a PE ratio of -14.00 and a beta of 1.31. Organogenesis has a fifty-two week low of $2.04 and a fifty-two week high of $7.08. The company has a debt-to-equity ratio of 0.05, a quick ratio of 3.16 and a current ratio of 3.53.

Organogenesis (NASDAQ:ORGO) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.08). Organogenesis had a positive return on equity of 9.63% and a negative net margin of 0.84%.The business had revenue of $37.23 million during the quarter, compared to the consensus estimate of $43.26 million.

Insider Transactions at Organogenesis

In other news, Director Michael Joseph Driscoll acquired 10,000 shares of Organogenesis stock in a transaction on Monday, March 9th. The stock was acquired at an average cost of $2.67 per share, with a total value of $26,700.00. Following the transaction, the director owned 225,707 shares of the company’s stock, valued at approximately $602,637.69. This trade represents a 4.64% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 33.00% of the company’s stock.

Institutional Investors Weigh In On Organogenesis

A number of institutional investors have recently added to or reduced their stakes in ORGO. Quarry LP bought a new stake in Organogenesis in the 3rd quarter worth about $25,000. Flagship Harbor Advisors LLC bought a new stake in Organogenesis in the 4th quarter worth about $34,000. Federated Hermes Inc. grew its position in Organogenesis by 52.8% in the 4th quarter. Federated Hermes Inc. now owns 8,541 shares of the company’s stock worth $44,000 after purchasing an additional 2,953 shares in the last quarter. Walleye Capital LLC bought a new stake in Organogenesis in the 2nd quarter worth about $45,000. Finally, Mercer Global Advisors Inc. ADV bought a new stake in Organogenesis in the 4th quarter worth about $57,000. 49.57% of the stock is owned by institutional investors.

About Organogenesis

Organogenesis Inc operates as a regenerative medicine company focused on the development, manufacturing and commercialization of therapeutic solutions for wound care, surgical repair and sports medicine. The company’s product portfolio addresses a range of acute and chronic tissue repair needs, leveraging bioengineered skin substitutes, human placental-derived products and other allografts designed to promote healing and reduce scarring. Organogenesis markets its therapies to hospitals, outpatient clinics, wound care centers and other healthcare providers.

Key offerings include Apligraf, a living skin substitute for treatment of diabetic foot ulcers and venous leg ulcers; Dermagraft, a cryopreserved human fibroblast-derived dermal substitute; Grafix, a placental membrane allograft for complex and chronic wounds; and TheraSkin, a cryopreserved human skin allograft used in surgical and reconstructive procedures.